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ABSTRACT — OBJECTIVE: The etiology of 
preterm labor is multifactorial. An inflamma-
tory response is always involved with the acti-
vation of NF-kB that determines synthesis and 
release of inflammatory molecules, implicated 
in fetal membrane activation, cervical mod-
ifications, abdominal pain and spontaneous 
uterine contractions. There is a close rela-
tionship between preterm birth and cervical 
shortening in the second quarter of pregnan-
cy. We evaluated the benefits of alpha-lipoic 
acid administration on women considered at 
risk of preterm delivery due to the presence 
of symptoms (pelvic pain and uterine contrac-
tions) or reduced cervical length.
PATIENTS AND METHODS: This prospec-
tive observational study was carried out at 
the Gynecology and Obstetrics Unit of Paler-
mo University Hospital (Palermo, Italy), from 
October 2015 to April 2016. The inclusion 
criteria were: women aged 18-35, with ges-
tational age between 24 and 33 weeks of 
amenorrhea, pregnancy at risk of preterm de-
livery due to cervical length between 35-25 
mm (in presence of symptoms) or < 30 and > 
15 mm (if asymptomatic), intact membranes 
and negative for vaginosis. Patients were 
treated daily with alpha lipoic acid orally (300 
mg, twice a day for 30 days) and vaginally 
(10 mg, once a day for 10 days), or untreat-
ed (controls). Patients were evaluated at the 
baseline (T 0), after 7 days, after 30 days, 
and at 34 weeks of gestation considering: 
maternal characteristics, symptomology and 
cervical length.
RESULTS: Among 60 analyzed women, 50 
were treated orally and vaginally with al-
pha-lipoic acid, whereas 10 did not undergo 
any therapy. In the treated group, 10 patients 
were asymptomatic and 40 symptomatic. The 
symptoms disappeared in 37 patients. In the 
untreated group, 4 women were symptomatic 
and 6 asymptomatic. At the end all wom-
en were symptomatic. Mean cervical length 
showed a reduction in the untreated group 
compared to the treated group.
CONCLUSIONS: The vaginal/oral-combined 
administration with alpha-lipoic acid showed 
effectiveness in reducing symptoms and 
preventing cervical shortening in our set of 
patients. No adverse effects were detected 
during the treatment. 
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incidence of premature delivery6. Previous evidence 
demonstrated the efficacy of vaginal progesterone in 
asymptomatic women affected by short cervix at mid 
pregnancy7. In this context it is important to identify 
a therapy, which is able to delay in substantial man-
ner, preterm delivery with very reduced or absent ad-
verse effects, even in presence of symptoms (uterine 
hypercontractility). 
Alpha-lipoic acid (ALA) is an organosulfur com-
pound with MW 206.32, a natural safe molecule at 
therapeutic doses, having several pleiotropic actions. 
It was isolated and chemically identified by Reed et 
al8. ALA is synthesized in plants and animals, but its 
production in humans is very low; tissues character-
ized by the presence of numerous mitochondria are 
the richest9. Potatoes, broccoli, spinach, tomatoes, 
Brussels sprouts, peas, and brown rice contain great 
quantities of this compound, but red meat (especially 
liver, heart, and kidney) is the most relevant source10. 
ALA was shown to exert a number of immunomod-
ulatory activities useful for preventing preterm de-
livery11. 
Based on these premises, our study was aimed 
at testing ALA administration in women at risk of 
preterm birth. 
PATIENTS AND METHODS
This prospective observational study was carried out 
at the Gynecology and Obstetrics Unit of Palermo 
University Hospital (Palermo, Italy), from October 
2015 to April 2016. It was approved by the Ethics 
Committee of our hospital.
Primary outcome of this trial was to evaluate the 
efficacy of ALA in decreasing the symptomatology 
affecting the patients and counteracting the process 
of cervical shortening. Patients were recruited from 
the 24th to 33rd week based on the cervicometric eval-
uation with transvaginal ultrasound, and/or the pres-
ence of pelvic pain. 
Pregnant women who turned to our clinic, were 
included among treated or untreated subjects with-
out randomization, obtaining a respective final ratio 
of 5:1. The control group was made up with patients 
who refused to be administered with ALA.
Women were asked to complete questionnaires 
focused on general health, behaviour and lifestyle, 
diet and drug use (spasmolytic/tocolytics) in previ-
ous pregnancies. 
Inclusion criteria:
 • aged between 18-35 years;
 • 24-33 weeks gestation;
 • intact membranes;
 • cervical length between 35-25 mm (in presence 
of symptoms) or < 30 and > 15 mm (if asymptom-
atic);
 • absence of bacterial vaginosis.
INTRODUCTION
Preterm delivery is characterized by the onset of reg-
ular uterine contractions in association with progres-
sive cervical shortening and dilatation. Premature 
activation of fetal membranes (FM) and remodeling 
of cervical collagen are the main events that speed 
up preterm birth1. According to WHO, preterm is 
defined as babies born alive before 37 weeks of preg-
nancy are completed.
In most of the developed countries its incidence 
goes from 5% to 10%. Preterm birth may be associ-
ated with neonatal complications, which can appear 
forthwith or later. Disorders such as neurodevelop-
mental delay, cerebral palsy and chronic lung disease 
are the major consequences for long-term morbidity. 
The neonatal outcome is linked to the gestational age 
at childbirth and associated features (i.e. infections). 
Obviously, the risk of mortality and morbidity grows 
in inverse proportion to the increase of gestational 
age. The prevention and treatment of preterm labor 
need that the expectant mothers at risk are identified 
on time; this diagnosis remains a key challenge. The 
risk of preterm delivery increases with the length re-
duction of uterine cervix. For this reason, the mea-
surement of cervical length can be used as a predic-
tor. The transvaginal ultrasound (TVS) is the most 
reliable technique for measuring the cervical canal. 
It is the first-choice method for evaluating the cervi-
cal length finalized to identify women with singleton 
pregnancy at risk of preterm delivery. 
The etiology of this complication is multifacto-
rial; however, the mechanism underlying such pro-
cess has still to be wholly understood. The infection 
alone may be insufficient to cause preterm birth, 
which is often the result of a complex interaction be-
tween microbial environment and immune response 
activated by the host. In this way, many inflamma-
tory mediators are synthesized and secreted in the 
maternal genital tract and fetal tissues; among such 
mediators pro-inflammatory cytokines, prostaglan-
dins and matrix metalloproteinase (mainly MMP-9) 
play a crucial role2. Furthermore, a close relationship 
with the inflammatory response was demonstrated in 
over 40% of cases. In this context also, the oxytocin 
receptors were found to play an inducing role. Cur-
rent treatments take advantage of corticosteroids and 
tocolytics (beta-mimetics, calcium channel blockers, 
non-steroidal anti-inflammatory drugs). However, 
antenatal corticosteroid administration was proven 
detrimental in various respects3-5. On the other hand, 
since preterm birth is caused by several factors, such 
as early activation of cervical ripening, and decidua, 
as well as uterine contractility, tocolytic drugs are 
not able to intervene on all the pathophysiological 
elements. Namely, tocolytic agents act only by re-
ducing more or less drastically, contractile uterine 
activity and, therefore, they can’t alone decrease the 
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p-value <0.05 was considered statistically signifi-
cant. Then, a logistic regression model was devel-
oped for all study variables.
RESULTS
This clinical study enrolled 60 healthy pregnant 
women aged between 21 and 33 years. They were 
included into two groups: 50 patients received the 
combined oral and vaginal ALA-based treatment 
and 10 were untreated (Fig. 1). At the recruitment, in 
the treated group, 10 patients were asymptomatic and 
40 symptomatic (pelvic pain). The 10 asymptomatic 
patients were all multiparas with previous full-term 
pregnancy: all these patients remained asymptom-
atic throughout pregnancy. Among 40 symptomatic 
women, 25 were primiparas and 15 multiparas. 
During the observational period, only one prim-
iparous remained symptomatic, but she still gave 
birth after 34 weeks, therefore after the last follow up. 
Among the 15 multiparas, 4 of them had had a previ-
ous preterm birth (before 34 weeks). In this last group 
of patients (multiparous, symptomatic and with a his-
tory of PTB) two remained symptomatic, one giving 
birth before 34 weeks, and the other one at term.
Therefore, among the 40 symptomatic women, 37 
got benefit by the therapy and become asymptomat-
ic, whilst 3 of them remained symptomatic but only 
one gave birth before 34 weeks.
Overall in the treated group only one patient de-
livered before 34 weeks. She was multiparous with a 
history of previous PTB.
In control group, 6 patients were asymptomatic 
and 4 were symptomatic; among the latter, 3 were 
primiparas and among them, 2 remained symptom-
atic and gave birth after 34 weeks, whereas 1 contin-
Exclusion criteria:
 • pregnancy at high risk;
 • pre-existing diabetes mellitus or systolic pressure 
≥140 mmHg at the enrolment;
 • diagnosis of diseases such as cancer, lupus, hepa-
titis, HIV/AIDS;
 • alcohol abuse, drug use;
 • positive swab for bacterial vaginosis, Chlamydia 
trachomatis and Neisseria gonorrhoeae;
 • previous treatments with tocolytic agents or pro-
gestogens in the last 8 weeks.
All patients were made aware about the treatment 
and risks. Moreover, they were informed to be not 
eligible for a different therapy. All patients signed an 
informed consent. 
Maternal characteristics (obstetric history, age, 
BMI, smoking, race) were recorded at the enrolment 
day (T0). The treatment consisted of one vaginal 
capsule/die (DAV® vaginal capsules, Lo.Li. Pharma 
srl (Rome, Italy), containing 10 mg ALA each cap-
sule) per 10 days and two oral tablets/die (DAV®, Lo.
Li.Pharma srl, Rome, Italy, containing 300 mg ALA 
each tablet) per 30 days. 
The included patients were further subdivided ac-
cording to the presence of symptoms of prematurity 
into two sub-groups: symptomatic or asymptomatic. 
These two groups were followed up until delivery. 
The clinical and instrumental monitoring was car-
ried out at the following times:
T0: enrolment day; T1: after 7 days; T2: after 30 
days; T3: at 34 weeks of gestation.
Each control comprised cervicometric evalua-
tion with transvaginal ultrasound, cardiotocograph-
ic trace to monitor uterine contractions, assessment 
of possible vaginal bleeding and/or membrane rup-
ture. The comparison between the two groups was 
performed by means of the Fisher’s exact test. The 
Figure 1. Flow chart of the study and patients’ characteristics
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treated and all remained stationary, instead 6 were 
not treated and all of them showed a worsening of 
symptoms. Between the two groups (treated and 
untreated), symptomatic patients were 44; 40 re-
ceived ALA and 37 of them reported a symptoms 
improvement, only three did not show any vari-
ation. In the remaining 4 subjects (without treat-
ment) the situation remained unchanged. Mean cer-
vical length showed a significant lessening between 
T0 and T3 in the untreated group compared to the 
treated one. Among ALA patients, at recruitment 
mean cervical length was 29.82 mm; at T3 it was 
28.93 mm (reduction: 2.98%). Instead, in the un-
treated group it was 29.7 mm and then 26.25 mm 
(reduction: 11.6%).
ued to be affected by symptoms and delivered at 32 
weeks. Among the symptomatic women, only 1 was 
multiparous with previous PTB before 28 weeks; she 
remained symptomatic, and gave birth at 28 weeks. 
Therefore, between 4 symptomatic untreated pa-
tients, they all continued to be affected by symptoms 
and 2 of them delivered before 34 weeks. In the 6 
asymptomatic untreated women (2 nulliparous and 
4 multiparas), symptoms appeared during the study; 
however, birth occurred after 34 weeks (Table 1).
Treatment efficacy was evaluated and resulted 
significant both in maintaining the absence of symp-
toms and in decreasing them (Table 2a and b). 
Between the two groups (treated and untreated) 
asymptomatic patients were 16; 10 of them were 
Table 1. Symptoms and pregnancy outcome according to groups. 
 Patients’ characteristics Outcomes
Patients Treatments   Symptoms  Parity and Symptoms Delivery
 (n)     at T0   history
    of PTB  ≤ 34 weeks > 34 weeks 
     
60 50 ALA   40 with  25 primiparas 1 patient: symptoms lasted     1
     symptoms   during the study
    24 patients: symptoms     24
     disappeared during the study   
   15 multiparas 2 patients: symptoms lasted 1 (previous    1
    (4 previous  during the study  PTB)  
      PTB) 13 patients: symptoms     13
     disappeared during 
     the treatment  
    10 without  10 multiparas 10 patients: no symptoms    10
     symptoms   occurred throughout 
     the study 
 10 untreated   4 with  3 primiparas 3 patients: symptoms lasted   1    2
     symptoms   during the study  
     1 multiparous 1 patient: symptoms lasted  1
      (1 previous PTB)  during the trial
    6 without 2 nulliparas 2 patients: symptoms    2
     symptoms   appeared during the study  
   4 multiparas 4 patients: symptoms appeared     4
     during the study
Table 2a. Symptoms evaluation in asymptomatic patients. 
*Fisher’s exact test: p-value = 0.001 vs. no treatment.
Asymptomatic patients at T0 Stationary Worsened Total
Treatment 10* 0 10
No treatment  0 6  6
 10 6 16
Table 2b. Symptoms evaluation in symptomatic patients. 
*Fisher’s exact test: p-value = 0.001 vs. no treatment.
Symptomatic patients at T0 Improved Not improved Total
Treatment 37* 3 40
No treatment  0 4  4
 37 7 44
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by other variables too (Table 3). The p-value showed 
that there were no significant differences by race and 
maternal age and that at T1 the symptoms were al-
most exclusively influenced by the treatment, while at 
T3 other variables such as BMI (p<0.013), smoking 
(p<0.025) and obstetric history (p<0.014) became sig-
nificant in conditioning the response to the treatment.
Comparison of cervical length over time
The averages of the cervical length were calculated 
and compared between the groups, at T0 (enrolment 
day), T1 (after 7 days), T2 (after 30 days) and T3 (at 
34 weeks of gestation) (Fig. 3). The graph shows that 
over time the treated patients had a minor reduction 
of the cervical length compared to the untreated 
ones. At the recruitment, in the ALA group the mean 
cervical length was 29.82 mm; at T3 28.94 mm (per-
centage reduction: 2.98%), instead in the untreated 
group the mean cervical length was 29.7 mm at T0 
and 26,25 mm at T3 (percentage reduction: 11.6%). 
The difference between the two groups at T3 was 
found significant (p-value = 0.006).
Finally, the logistic regression model was used 
again to figure out if the smaller lessening of the cer-
vical canal in the treated group was only due to the 
treatment or was caused by other variables.
The p-values show that at T3 the different de-
crease of the cervical length is determined not only 
by the treatment, but also by other factors, such 
as BMI (p<0.000), smoking (p<0.024), previous 
preterm birth (p=.000).
Comparison of symptoms over time
In the graph can be seen the symptoms improvement 
of the treated patients, at T0 (enrolment day), T1 (af-
ter 7 days), T2 (after 30 days) and T3 (at 34 weeks 
of gestation) (Fig. 2). At the recruitment (T0) 80% of 
women to be administered with ALA, was symptom-
atic, whereas at T3 only 6% were still symptomatic 
and 94% remained or became asymptomatic. Instead, 
at the recruitment (T0) 40% were symptomatic in the 
control group and at T3 100% became symptomat-
ic. We subsequently developed a logistic regression 
model to figure out if the symptoms improvement 
was induced only by the treatment or was influenced 
Figure 2. Comparison of symptoms overtime per group.
Table 3. Logistic regression model related to symptom (pelvic pain) at T1 and T3 
Pelvic pain T1 Coef. Std.Err. t P>|t| 95% Conf. Interval
Age .0108625 .0177976 0.61 0.544 -.0248851 .0466101
BMI .0252463 .014709 1.72 0.092 -.0042976 .0547903
Race -.0339228 .0454798 -0.75 0.459 -.1252718 .0574261
Smoking .1349882 .0994971 1.36 0.181 -.0648576 .3348339
Primiparous -.0763835 .1557947 -0.49 0.626 -.3893064 .2365394
Previous Preterm Birth < 34 weeks .4394954 .2368892 1.86 0.069 -.0363105 .9153013
Previous Preterm Birth > 34 weeks -.0565818 .2160546 -0.26 0.794 -.4905402 .3773766
Previous Term Birth -.0939638 .1613254 -0.58 0.563 -.4179955 .2300678
Treated -.4314717         .0954872 -4.52 0.000 -.6232634 -.23968
_cons -.3588863 .6223751 -0.58 0.567 -1.608963 .8911908
Pelvic pain T3 Coef. Std.Err. t P>|t| 95% Conf. Interval
Age .0175693 .0113661 1.55 0.128 -.0052602 .0403987
BMI .0242824 .0093936 2.58 0.013 .0054147 .04315
Race -.0254152 .0290448 -0.88 0.386 -.0837534 .0329229
Smoking .1472408 .0635417 2.32 0.025 .0196135 .2748681
Primiparous .1439646 .0994951 1.45 0.154 -.0558772 .3438063
Previous Preterm Birth < 34 weeks .3841629 .1512844 2.54 0.014 .0802993 .6880265
Previous Preterm Birth > 34 weeks .366513 .1379788 2.66 0.011 .0893744 .6436515
Previous Term Birth .1880698 .1030271 1.83 0.074 -.0188664 .3950059
Treated -.8447964 .0609809 -13.85 0.000 -.9672802 -.7223126
_cons -.3684833 .397467 -0.93 0.358 -1.166819 .4298526
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concerning ALA activity support the effect we found. 
Some researches and studies demonstrated ALA ef-
ficacy in reducing the expression of matrix metal-
loproteinase (MMP)-916 and in countering TNF-in-
duced and thrombin-induced weakening of human 
foetal membranes17,18. Moreover, ALA administration 
in vitro lessened the secretion of inflammatory cyto-
kines, such as TNF-α, IL-1β, and IL-6, induced by 
LPS stimulation in rat mesangial cells19. A similar de-
crease was detected for prostaglandin E2 (PGE2) and 
nitric oxide (NO), due to cyclooxygenase-2 (COX-2) 
and inducible nitric oxide synthase (iNOS) inhibition 
by ALA pre-treatment19. Furthermore, ALA inhibits 
the expression of the inflammatory cytokine IL-820 
and enhances IL-10 mRNA21. Moreover, recent clin-
ical trials strengthened ALA profile as an effective 
immunomodulatory molecule to counteract some in-
flammatory disorders during pregnancy. Porcaro et 
al22 carried out a randomized controlled clinical trial 
in pregnant women with threatened miscarriage. The 
study group was administered orally with ALA (600 
mg/die) plus vaginal suppositories containing proges-
terone, whereas controls received only progesterone 
by vaginal route. The aim was to test the improvement 
of progesterone therapy for healing subchorionic he-
matomas and also for reducing subjective and objec-
tive signs such as vaginal bleeding, abdominal pain, 
and uterine contractions. The trial showed that ALA 
plus progesterone significantly improved the hemato-
ma resorption compared to progesterone effect alone. 
In the study group was observed a faster reduction 
or disappearance of all symptoms in comparison to 
controls; however, such difference was not significant. 
Another controlled randomized clinical trial was car-
ried out by Costantino et al23 in women with threat-
ened miscarriage to evaluate the effect of ALA (10 
mg/die) or progesterone (control), both administered 
by vaginal route, in subchorionic hematoma resorp-
tion. In the treated group with ALA the subchori-
onic hematoma was significantly reabsorbed faster 
compared to the progression found in progesterone 
patients. Of note, a smaller number of miscarriages 
occurred in the ALA group compared to controls. Fi-
nally, a recent randomized clinical trial by Facchinetti 
et al24, in women at risk of preterm labor, compared 
the effects of vaginal ALA (400 mg/die) to placebo. 
The authors demonstrated that the treatment signifi-
cantly stimulated anti-inflammatory cytokines release 
in the cervix of patients at risk of PTB after primary 
tocolysis, and it was associated with a stabilization of 
the cervical length. All these effects agree with our re-
sults and give us a persuasive key of explanation. Ob-
viously, our study has some evident limitations. The 
small sample reduces the power of the study weak-
ening its promising results. The reduced incidence of 
this pathology, and consequently the low incidence 
of positive obstetric history of preterm birth, makes 
necessary the realization of a multicentre trial for the 
DISCUSSION
This study showed that ALA supplementation during 
the second trimester has proven effective in reducing 
the symptomatology as well as in preventing both 
the onset of symptoms and the cervical shortening 
in women at risk of preterm delivery. In agreement 
with previously reported studies11,12, ALA admin-
istration was safe at therapeutic doses in pregnant 
women, without any adverse effect. 
Birth after the last monitoring (34 weeks of ges-
tation) was considered as parameter of efficacious 
treatment. The new classification criteria consider it 
“late preterm” as correlated with significantly higher 
prognosis and survival rate than the childbirths occur-
ring in the previous weeks. One of the most important 
parameters for medical history evaluation of the ex-
amined patients was a positive obstetric anamnesis for 
previous preterm birth. In fact, treatment with ALA 
was successful in reducing preterm delivery rate be-
fore 34 weeks in women with negative obstetric an-
amnesis and in those with previous moderate preterm 
birth, whereas it showed a relative efficacy in women 
with previous “low preterm” delivery. This may be 
related to the multifactorial aetiology of preterm la-
bor. Despite the knowledge of its etiopathogenesis is 
considerably improved in the last decades, many of 
the underlying mechanisms remain to be elucidated. 
As mentioned before, in preterm delivery inflamma-
tory mediators are synthesized and secreted in the 
maternal genital tract and fetal tissues; among such 
mediators pro-inflammatory cytokines, prostaglan-
dins and matrix metalloproteinase (mainly MMP-9) 
play a crucial role2. As pro-inflammatory cytokine, 
IL-8 looks to be the most involved in the process of 
cervical ripening13, as well as matrix metalloprotein-
ase-914, which induces the degradation of the extra-
cellular matrix, and prostaglandin E215. Previous data 
Figure 3. Comparison of mean cervical length (CL) overtime 
per group.
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Sci 2017; 21: 4219-4227.
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16. Kim HS, Kim HJ, Park KG, Kim YN, Kwon TK, Park JY, 
Lee KU, Kim JG, Lee IK. Alpha-lipoic acid inhibits matrix 
metalloproteinase-9 expression by inhibiting NF-kappaB 
transcriptional activity. Exp Mol Med 2007; 39: 106-113.
17. Moore RM, Novak JB, Kumar D, Mansour JM, Mercer 
BM, Moore JJ. Alpha-lipoic acid inhibits tumor necrosis 
factor-induced remodeling and weakening of human fetal 
membranes. Biol Reprod 2009; 80: 781-787.
18. Moore RM, Schatz F, Kumar D, Mercer BM, Abdelrahim 
A, Rangaswamy N, Bartel C, Mansour JM, Lockwood CJ, 
Moore JJ. Alpha-lipoic acid inhibits thrombin-induced fetal 
membrane weakening in vitro. Placenta 2010; 31: 886-892.
19. Li G, Fu J, Zhao Y, Ji K, Luan T, Zang B. Alpha-lipoic 
acid exerts anti-inflammatory effects on lipopolysaccha-
ride-stimulated rat mesangial cells via inhibition of Nuclear 
Factor Kappa B (NF-κB) signaling pathway. Inflammation 
2015; 38: 510-519.
20. Choi JH, Cho SO, Kim H. α-Lipoic acid inhibits expression 
of IL-8 by suppressing activation of MAPK, Jak/Stat, and 
NF-κB in H. pyloriinfected gastric epithelial AGS cells. 
Yonsei Med J 2016; 57: 260-264.
21. Tanaka Y, Kaibori M, Miki H, Nakatake R, Tokuhara K, 
Nishizawa M, Okumura T, Kwon AH. Alpha-lipoic acid 
exerts a liver-protective effect in acute liver injury rats. J 
Surg Res 2015; 193: 675-683. 
22. Porcaro G, Brillo E, Giardina I, Di Iorio R. Alpha lipoic 
acid (ALA) effects on subchorionic hematoma: preliminary 
clinical results. Eur Rev Med Pharmacol Sci 2015; 19: 
3426-3432.
23. Costantino M, Guaraldi C, Costantino D. Resolution of 
subchorionic hematoma and symptoms of threatened mis-
carriage using vaginal alpha lipoic acid or progesterone: 
clinical evidences. Eur Rev Med Pharmacol Sci 2016; 20: 
1656-1663.
24. Grandi G, Pignatti L, Ferrari F, Dante G, Neri I, Facchinetti 
F. Vaginal alpha-lipoic acid shows an anti-inflammatory 
effect on the cervix, preventing its shortening after primary 
tocolysis. A pilot, randomized, placebo-controlled study. J 
Matern Fetal Neonatal Med 2017; 30: 2243-2249.
collection of a suitable sample size. Our findings con-
firm the literature data with respect to tobacco smoke 
during pregnancy, and high BMI. In fact, smoking and 
obesity are related significantly to reduced treatment 
response and consequently increased risk of preterm 
delivery. Our study was the first one that evaluated 
the efficacy of the combination of ALA using together 
the oral and vaginal administration in women select-
ed through cervicometry parameters, with or without 
symptoms, and monitored over time through trans-
vaginal ultrasound which represents the most reliable, 
objective and reproducible measurement technique of 
the cervical canal.
CONCLUSIONS
This study demonstrated that the combined adminis-
tration with ALA by oral and vaginal route obtained 
a statistically significant improvement of symptoms, 
with a reduced cervical shortening in patients at risk 
for preterm birth. The success of this new treatment 
in threatened preterm delivery would seem posi-
tively linked to a history of previous preterm birth, 
smoking and high maternal BMI. It is necessary to 
extend this study to a larger and randomized sample 
to confirm the therapy effectiveness.
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